Summit Therapeutics, which is developing novel therapies for muscular dystrophy and bacterial infections, raised $34 million by offering 3.45 million shares at $9.90, below its expected offer price of $11.54. Summit Therapeutics, which already trades on the AIM under the ticker SUMM, will list on the NASDAQ under the symbol SMMT. JMP Securities and Oppenheimer & Co. acted as joint bookrunners on the deal.
